Arzneimittelnebenwirkungen in der Gastroenterologie

• Literatur

• 1 Schweikert-Wehner PM. Protonenpumpenhemmer: Wie sich die Bioverfügbarkeit anderer Arzneistoffe verändert. Dtsch Arztebl 2016; 113: A1102
• 2 Chu MP, Ghosh S, Chambers CR. et al. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 2015; 16: 33-39
• 3 Sharma M, Holmes HM, Mehta HB. et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 2019; 125: 1155-1162
• 4 Mir O, Touati N, Lia M. et al. Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated wthin the EORTC 62043/62072 trials. Clin Cancer Res 2019; 25: 1479-1485